Your session is about to expire
Lumigan vs Travatan
Introduction
For patients with glaucoma or other types of ocular hypertension, certain drugs that reduce the pressure within the eye can help in stabilizing vision and preventing further damage. Lumigan and Travatan are two such drugs that are prescribed for these conditions. They each impact the drainage system in the eye, but both have pressure-reducing effects in patients with glaucoma or ocular hypertension. Lumigan is a prostaglandin analogue which works by increasing the outflow of aqueous humor from within the eye to lower intraocular pressure. Travatan, on the other hand, is also a prostaglandin analog but it works slightly differently as it not only increases uveoscleral outflow (as does Lumigan) but also reportedly enhances trabecular meshwork outflow - another route for fluid to leave your eyes.
Lumigan vs Travatan Side By Side
| Attribute | Lumigan | Travatan |
|---|---|---|
| Brand Name | Lumigan | Travatan |
| Contraindications | Should not be used with certain heart or blood pressure medications (including beta-blockers). Can cause permanent darkening of the iris and thickening of eyelashes. | Should not be used with certain heart or blood pressure medications (including beta-blockers). May cause darkening of the colored part of your eye and eyelash changes. |
| Cost | Around $240 for a 2.5 ml bottle of Lumigan (0.03%) or $50 to $100 per 3 ml bottle for the generic version | About $180 for a 2.5ml bottle of Travatan Z (0.004%) or $40 to over $90 for a similar-sized bottle for the generic version |
| Generic Name | Bimatoprost | Travoprost |
| Most Serious Side Effect | Allergic reactions, signs of eye infection, changes in the color of your eyes, thickening and darkening of eyelashes, blurred vision, unusual heart rhythm, low sodium levels, severe reaction within nervous system. | Allergic reactions, changes in vision, discoloration of the iris and eyelid changes, redness in the eyes or signs of infection, increased sensitivity to light. |
| Severe Drug Interactions | Negative interactions with certain heart or blood pressure medications. | Negative interactions with certain heart or blood pressure medications. |
| Typical Dose | One drop in the affected eye(s) once daily, typically in the evening. | 1 drop in the affected eye(s) once daily, preferably in the evening. |
What is Lumigan?
Bimatoprost (the generic name for Lumigan) and Travoprost (generic for Travatan) are both prostaglandin analogs, a newer class of glaucoma drugs that marked a significant advance over the previous generation of beta-blockers. Bimatoprost was first approved by the FDA in 2001. Lumigan works by increasing the outflow of fluid from the eye, thereby effectively lowering intraocular pressure for longer periods than usual. It is prescribed primarily to treat different forms of open-angle glaucoma and ocular hypertension. Though they have similar mechanisms of action, there are some differences between these two medications. Lumigan has been found to be slightly more effective at reducing intraocular pressure but may have a higher incidence of conjunctival hyperemia (red eyes). On the other hand, Travatan tends to cause less redness but may not reduce pressure as much as Lumigan does.
What conditions is Lumigan approved to treat?
Lumigan is approved for the treatment of certain eye conditions:
- Open-angle glaucoma, one of the most common forms of glaucoma.
- Hypertension in the eyes, where it helps lower high pressure inside eyes which can lead to an illness called ocular hypertension
- Used when other drugs are not sufficient or have caused unwanted side effects.
How does Lumigan help with these illnesses?
Lumigan helps to manage glaucoma by increasing the outflow of aqueous humor, a fluid in the eye. It does this by mimicking prostaglandins, compounds that among other things can increase the outflow of aqueous humor. Aqueous humor is a transparent liquid in the front part of our eyes which provides nourishment to nearby tissues and maintains intraocular pressure (IOP). In conditions like glaucoma, there's an imbalance between production and drainage of this fluid leading to increased IOP which may damage optic nerves causing vision loss. Therefore, by enhancing aqueous humor outflow using Lumigan results in decreased IOP helping patients with open-angle glaucoma or ocular hypertension manage their condition and prevent further loss of vision.
What is Travatan?
Travatan, also known as Travoprost, is a type of medication classified as a prostaglandin analogue. Similar to Lumigan (Bimatoprost), it primarily serves to treat conditions such as glaucoma and ocular hypertension by increasing the outflow of aqueous fluid from the eyes which reduces intraocular pressure. However, unlike Bimatoprost, Travoprost does not stimulate melanogenesis. This difference in action means that its side-effect profile differs somewhat from that of Lumigan - particularly in terms of less potential for changes in iris color or eyelash growth.
Travatan was first approved by the FDA in 2001 and is available via prescription. It comes typically as an ophthalmic solution which needs to be administered directly into affected eyes once daily. The impact on intraocular pressure can make it a beneficial treatment option especially for patients who don't respond well or have contraindications with other typical glaucoma medications.
What conditions is Travatan approved to treat?
Travatan is an FDA-approved medication indicated for the reduction of:
- Elevated intraocular pressure (IOP) in patients with open-angle glaucoma
- Ocular hypertension, which can lead to vision loss if left untreated.
How does Travatan help with these illnesses?
Prostaglandins are naturally occurring substances in the body that play a significant role in eye health, including maintaining adequate ocular pressure. Travatan, similar to Lumigan, works by mimicking prostaglandins to increase the outflow of fluid from the eye and reduce intraocular pressure. This action helps to prevent damage to the optic nerve and potential vision loss associated with conditions like glaucoma. Travatan distinguishes itself through its specific formulation and dosing schedule that may provide more consistent 24-hour IOP control for some patients than Lumigan. Moreover, it's generally well-tolerated with fewer instances of conjunctival hyperemia (red eyes), which is a common side effect associated with these types of medications.
How effective are both Lumigan and Travatan?
Both bimatoprost (Lumigan) and travoprost (Travatan) are prostaglandin analogs, highly effective in reducing intraocular pressure in patients with glaucoma or ocular hypertension. These medications were approved by the FDA within a few years of each other at the start of the new millennium. As they act on similar receptors but have different molecular structures, they may be prescribed under different circumstances.
A randomized clinical trial conducted in 2001 demonstrated that Lumigan and Travatan had comparable efficacy in lowering intraocular pressure. Both drugs showed promising safety profiles, though some differences emerged between them regarding side-effects: Lumigan was somewhat more likely to lead to conjunctival hyperemia - an increased blood flow that can cause redness and discomfort.
In a meta-analysis of several studies published during 2002 - 2010 period, Lumigan demonstrated its effectiveness from the first month of treatment. It has been shown to reduce intraocular pressure significantly more than timolol -- another common medication for glaucoma -- making it one of the most potent options available. In addition to being well-tolerated among various populations, including elderly patients with comorbidities like heart disease or diabetes, it's also beneficial for those who require around-the-clock control because it works consistently throughout day and night.
Similarly reviewed in multiple clinical trials is Travatan's efficacy against placebo or timolol as a monotherapy or adjunctive therapy for glaucoma. While it typically falls into second-line treatments due to cost considerations compared with older therapies such as beta-blockers or carbonic anhydrase inhibitors; significant research shows its value when added alongside these first-line treatments. Nonetheless, evidence supporting Travatan as superior over other prostaglandin analogs remains inconclusive.
What sets these two drugs apart might come down to individual patient’s response and tolerance towards their respective adverse effects; where some people might prefer avoiding Lumigan due to higher tendency causing eye redness while others might find changes caused by Travatan like darkening eyelashes less desirable.
Related trials for lumigan and travatan
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Lumigan typically prescribed?
Dosages of Lumigan range from one drop in the affected eye(s) once daily, typically in the evening. Studies have indicated that this dosage is sufficient for reducing elevated intraocular pressure (IOP) in most people. Children and adolescents may also be started on a similar regimen under medical supervision. In either population, it's important to use Lumigan as directed by your healthcare provider. If there is no response after several weeks of treatment, consult with your healthcare provider but do not increase the dosage without their guidance. The maximum frequency that should not be exceeded in any case is once daily.
At what dose is Travatan typically prescribed?
Travatan treatment is typically initiated at a dosage of 1 drop in the affected eye(s) once daily, preferably in the evening. If one dose is missed, treatment should continue with the next dose as planned. The dosing frequency should not exceed once daily since it has been shown that more frequent administration may decrease the intraocular pressure lowering effect. It's important to remember that maximum IOP reduction is usually achieved within approximately two weeks and maintained over periods of up to four years. However, regular monitoring by your healthcare provider remains vital throughout this period.
What are the most common side effects for Lumigan?
Common side effects of Lumigan and Travatan may include:
- Redness, itching, or burning of the eyes
- Dry eyes or watery eyes
- Blurred vision
- Changes in eyelash color, length, thickness or number
- Darkening of the skin around the eye (more common with Lumigan)
- Sensitivity to light
- Headache
- Dizziness -Stinging or discomfort after applying the drops
It's important to note that while these medications can have similar side effects, they might not affect everyone in the same way. If you experience any severe symptoms such as changes in vision or intense eye pain after using these medications, it is recommended to seek immediate medical attention.
Are there any potential serious side effects for Lumigan?
In comparison, Lumigan and Travatan are both medications used to treat glaucoma. However, they may cause different side effects in some patients:
- allergic reactions such as hives or itching, difficulty breathing or swallowing, swelling of the face or throat
- signs of eye infection: redness, discomfort, drainage and/or visual changes
- changes in the color of your eyes (increase in brown pigment) which could be permanent
- thickening and darkening of eyelashes on the treated eye(s)
- blurred vision -unusual heart rhythm palpitations or fluttering sensations in chest; shortness of breath that comes suddenly; low sodium levels - this can lead to symptoms like confusion, headache, weakness at extreme level causing unsteadiness. -uncommon but severe reaction within nervous system – rigid muscles with high fever possibly leading to sweating profusely; uneven fast heartbeats followed by tremors might make you feel faint.
If any serious side effects occur while using either Lumigan or Travatan contact a medical professional for advice immediately.
What are the most common side effects for Travatan?
With Travatan, some users might experience:
- Mild eye discomfort
- Stinging or burning of the eyes after using the drops
- A feeling like something is in your eye
- Blurred vision, visual changes
- Eye redness or itching, eyelid swelling
- Increased sensitivity to light
- Headache, dizziness In rare cases, it can also darken the colored part of your eye and cause eyelash changes such as increased length, thickness and number of lashes. These changes occur slowly and you may not notice them for months or years.
Are there any potential serious side effects for Travatan?
While Travatan is generally well-tolerated, it's important to be aware of potential adverse reactions. These may include:
- Signs of an allergic reaction such as hives, itching, difficulty breathing or swallowing, swelling in your face or throat
- Changes in vision such as blurred vision, tunnel vision, eye pain or swelling
- Discoloration of the iris (the colored part of your eye) and eyelid changes including darkening and thickening
- Redness in the eyes or other signs of infection like discharge or crusting
- Increased sensitivity to light
If any notable changes occur after starting Travatan treatment - particularly those affecting your sight - discontinue use immediately and consult with a healthcare professional. Remember that while these side effects are listed they are not common occurrences but rather possibilities if one has an unusual reaction to the medication.
Contraindications for Lumigan and Travatan?
Both Lumigan and Travatan, like many other eye drop medications for glaucoma, may cause changes in vision or eyelash growth. If you notice an increase in floaters, flashes of light, a sudden decrease in vision, or any unusual eye symptoms, please seek immediate medical attention.
Neither Lumigan nor Travatan should be used if you are currently taking certain types of heart or blood pressure medication (including beta-blockers), as these can interact negatively with the active ingredients found in these drops. Always inform your physician about all the medicines you are currently on; some might require a period to clear from your system before starting treatment with Lumigan or Travatan.
It's also important to note that both eye drops can darken the color of your iris over time - this change is likely permanent. Additionally, they may cause darkening and thickening of your eyelashes and could potentially stimulate hair growth where they repeatedly come into contact with skin (for example: cheek area). Please discuss potential side effects thoroughly with your doctor before choosing between either medicine.
How much do Lumigan and Travatan cost?
For the brand name versions of these medications:
- The price of a 2.5 ml bottle of Lumigan (0.03%) averages around $240, which works out to approximately $80/month, considering an average use rate.
- The price for Travatan Z (0.004%), in contrast, is about $180 for a 2.5ml bottle or roughly $60/month.
Thus, if you are using either medication once daily as recommended by many physicians, then brand-name Travatan Z is less expensive on a per-month basis than Lumigan.
Please note that cost should not be your primary consideration when determining which eye drop solution is best suited to your needs and conditions such as glaucoma or ocular hypertension.
As far as generic versions go:
- Bimatoprost (the active ingredient in Lumigan) costs between $50 and $100 per 3 ml bottle depending upon the pharmacy chosen.
- Travoprost (generic form of Travatan), on the other hand, ranges from around $40 to over $90 for a similar-sized bottle.
Here too we see that typically, the generic version of Travatan can be somewhat more affordable than its counterpart in Lumigan - although prices do vary significantly between different sources or pharmacies.
Popularity of Lumigan and Travatan
Bimatoprost, in generic form as well as brand names such as Lumigan, was estimated to have been prescribed to about 3.2 million people in the US in 2020. Bimatoprost accounted for just over 15% of prostaglandin analog prescriptions in the US. These medications are primarily used to manage glaucoma and ocular hypertension by reducing intraocular pressure. The prevalence of bimatoprost has been steadily increasing since its approval by FDA.
Travoprost, including brand versions such as Travatan, was prescribed to approximately 1.5 million people in the USA during that same year. In the US, travoprost accounts for roughly 9% of prostaglandin analog prescriptions but is extensively known for its effectiveness and fewer side effects compared with other treatments available on market. There's been a slight decline recently due possibly because it’s costlier than some other drugs within this group.
Conclusion
Both Lumigan (bimatoprost) and Travatan (travoprost) are clinically proven to effectively treat high intraocular pressure, a common symptom of glaucoma. They work by increasing the outflow of fluid from the eye, thereby reducing pressure. Both drugs may be used in combination with other ocular hypertension medications if deemed necessary by an ophthalmologist, though they should not be administered concurrently due to their similar mechanisms of action.
Lumigan and Travatan have different active ingredients but belong to the same class of medication called prostaglandin analogs. In terms of efficacy, both drugs perform similarly; however, some patients might respond better to one over the other based on individual biochemical differences.
Both medications are available in generic form which can provide cost savings for patients paying out-of-pocket. The onset of effects may take several weeks as lowering intraocular pressure is a gradual process.
Side effects between these two treatments bear similarities too - redness or discomfort in eyes being among them - yet each has its unique side effect profile. For instance, Lumigan is more likely than Travatan to cause darkening around the eye area or eyelash growth changes. It's crucial that patients report any unusual symptoms immediately and consistently monitor their condition under medical supervision while undergoing treatment.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Eisenberg, D. L., Toris, C. B., & Camras, C. B. (2002, August). Bimatoprost and Travoprost. Survey of Ophthalmology. Elsevier BV.http://doi.org/10.1016/s0039-6257(02)00327-2
- Bournias, T. E., Lee, D., Gross, R., & Mattox, C. (2003, June). Ocular Hypotensive Efficacy of Bimatoprost When Used as a Replacement for Latanoprost in the Treatment of Glaucoma and Ocular Hypertension. Journal of Ocular Pharmacology and Therapeutics. Mary Ann Liebert Inc.http://doi.org/10.1089/108076803321908329
- Waugh, J., & Jarvis, B. (2002). Travoprost. Drugs & Aging. Springer Science and Business Media LLC.http://doi.org/10.2165/00002512-200219060-00005
- Hughes, B. A., Bacharach, J., Craven, E. R., Kaback, M. B., Mallick, S., Landry, T. A., & Bergamini, M. V. W. (2005, October). A Three-Month, Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Travoprost 0.004% Ophthalmic Solution and Timolol 0.5% Dosed Concomitantly in Subjects With Open Angle Glaucoma or Ocular Hypertension. Journal of Glaucoma. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/01.ijg.0000176935.08392.14
- Hylton, C., & Robin, A. L. (2003, April). Update on prostaglandin analogs. Current Opinion in Ophthalmology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/00055735-200304000-00001
- Covert, D., & Robin, A. L. (2006, April 19). Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Current Medical Research and Opinion. Informa Healthcare.http://doi.org/10.1185/030079906x104777